Safety and tolerability of combination antimalarial therapies for uncomplicated falciparum malaria in Ugandan children
-
* Corresponding author: Sarah G Staedke sarah.staedke@lshtm.ac.uk
Malaria Journal 2008, 7:106 doi:10.1186/1475-2875-7-106
Accesses
- Last 30 days: 40 accesses
- Last year: 472 accesses
- All time: 2767 accesses
Cited by
BioMed Central: 4 citations
|
Research
Julien Zwang, Jean-Louis Ndiaye, Abdoulaye Djimde, Grant Dorsey, Andreas Martensson, Corine Karema, Piero Olliaro Malaria Journal 2012, 11:25 (25 January 2012) Effect of different antimalarial treatments on haematologic parameters comparing artesunate-amodiaquine against various single treatment lines and combination therapies.
|
|
Research
Shereen Katrak, Anne Gasasira, Emmanuel Arinaitwe, Abel Kakuru, Humphrey Wanzira, Victor Bigira, Taylor G Sandison, Jaco Homsy, Jordan W Tappero, Moses R Kamya, Grant Dorsey Malaria Journal 2009, 8:272 (30 November 2009) While ACT is rapidly becoming the standard of care for uncomplicated malaria in most of Africa, there is limited data on the safety and tolerability of these drugs, especially in young children and patients co-infected with HIV.
|
|
Review
Safety profile of Coartem®: the evidence base Catherine Falade, Christine Manyando Malaria Journal 2009, 8(Suppl 1):S6 (12 October 2009) |
|
Research
Jean Ndiaye, Milijaona Randrianarivelojosia, Issaka Sagara, Philippe Brasseur, Ibrahima Ndiaye, Babacar Faye, Laurence Randrianasolo, Arsène Ratsimbasoa, Doris Forlemu, Vicky Moor, Aminata Traore, Yahia Dicko, Niawanlou Dara, Valérie Lameyre, Mouctar Diallo, Abdoulaye Djimde, Albert Same-Ekobo, Oumar Gaye Malaria Journal 2009, 8:125 (8 June 2009) A carefully-conducted clinical trial presenting a three-armed randomized, non-inferiority, multicentre study of a fixed-dose artesunate-amodiaquine combination either administered once or twice daily compared with standard artemether-lumefantrine treatment during a follow-up duration of 28 days with PCR-corrected cure rates.
|
